Lung Cancer: Durvalumab and Domvanalimab Study

We are studying a combination of two medications for patients with stage III unresectable non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this combination improves survival and disease control compared to standard treatment.

6-12 months 11-15 visits Confirmation phase (III)Post-Trial Drug Access Cost Reimbursement Partially Remote Investigational Medicines Oral InjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Imfinzi

Imfinzi is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Durvalumab

Durvalumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein tumors use to hide.

Infliximab

Infliximab is a substance that reduces inflammation by blocking a protein called TNF and is used for autoimmune conditions like rheumatoid arthritis and Crohn's.

Mycophenolate Mofetil

Mycophenolate mofetil is a substance that suppresses the immune system to prevent organ transplant rejection and treat autoimmune conditions.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Domvanalimab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Chirec

Chirec Cancer Institute (CCI)

Etterbeek, Belgium

CHU Helora

Service de Recherche Clinique (SeReC), Level 5A

Fayt-lez-Manage, Belgium

UZ Leuven

Pneumology

Heverlee, Belgium

Sponsor: Astrazeneca AB

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.